Clinical Updates and Market Opportunities for AUTO1 and AUTO3; ASH Day 3 Autolus Investor Event
On Monday, December 7, 2020, Autolus held an investor event (presentation / webcast) discussing recent advances to their AUTO1 (CD19 CAR-T) in ALL and AUTO3 (CD19/CD22 CAR-T) in DLBCL programs. Below, Celltelligence provides insights into AUTO3’s potential use in the outpatient setting and AUTO1’s market opportunity in adult and pediatric ALL.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.